Company Overview
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Why Investors Should Care
Revenue has grown at a 24.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $90.50M (+8.0% YoY); net profit $-54.00M.
- Trailing 12 Months Year-on-year growth — revenue -4.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.06% |
| 1 Year: | -4.60% |
Stock Price Performance
| 1 Year: | +43.51% |
| 6 Months: | +9.41% |
| 3 Months: | +44.44% |
| 1 Month: | +7.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross8d ago
- RSI (14)53.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LUNG Pulmonx Corporation R2KPHARMA | 2.21 | -1.92 | $93.34M | 0.00% | -49.13% | -88.87% | 24.06% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.78M | 7.37M | 9.10M | 10.35M | 8.62M | 3.67M | 10.61M | 9.83M | 9.24M | 12.20M | 13.26M | 10.79M | 13.95M | 13.50M | 14.54M | 17.19M | 17.67M | 18.85M | 20.78M | 20.39M | 22.54M | 23.86M | 21.50M | 20.59M | 22.76M |
| Gross Profit | 3.72M | 4.95M | 6.41M | 7.34M | 5.65M | 1.01M | 7.46M | 7.08M | 6.61M | 9.03M | 9.74M | 8.11M | 10.42M | 10.15M | 10.59M | 12.73M | 13.03M | 14.08M | 15.31M | 15.03M | 16.34M | 17.20M | 16.05M | 16.04M | 17.74M |
| Operating Income | - | - | -3.61M | - | -6.10M | -11.53M | -5.35M | - | -12.49M | -12.68M | -9.76M | -15.67M | -14.41M | -13.93M | -16.40M | -16.44M | -15.18M | -14.54M | -15.62M | -14.13M | -14.56M | -14.80M | -14.39M | -12.96M | -9.06M |
| Net Income | -6.13M | -5.57M | -4.33M | -4.67M | -7.16M | -11.91M | -3.86M | -9.30M | -12.51M | -12.96M | -10.18M | -15.83M | -14.64M | -14.17M | -15.86M | -16.20M | -14.90M | -13.75M | -15.33M | -14.14M | -14.45M | -15.17M | -13.96M | -13.65M | -10.08M |
| Diluted EPS | - | - | - | - | -3.76 | -6.15 | -1.37 | - | -0.35 | -0.36 | -0.28 | -0.43 | -0.40 | -0.38 | -0.42 | -0.43 | -0.39 | -0.36 | -0.39 | -0.36 | -0.36 | -0.38 | -0.34 | -0.33 | -0.24 |
| R&D Expense | - | - | 1.40M | - | 1.56M | 1.43M | 2.00M | - | 3.03M | 3.51M | 2.81M | 3.53M | 3.59M | 4.37M | 4.25M | 5.71M | 4.22M | 4.21M | 5.62M | 3.74M | 4.76M | 5.31M | 4.85M | 4.90M | 5.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.00M | 32.59M | 32.73M | 48.42M | 53.66M | 68.67M | 83.79M | 90.50M |
| Cost of Revenue | - | - | - | - | 13.80M | 17.92M | 21.79M | 23.36M |
| Gross Profit | 12.29M | 22.41M | 21.20M | 35.63M | 39.87M | 50.75M | 62.00M | 67.14M |
| Operating Expenses | - | - | - | - | 98.50M | 112.69M | 119.70M | 120.80M |
| Operating Income | -15.05M | -17.84M | -32.33M | -47.30M | -58.64M | -61.94M | -57.70M | -53.66M |
| EBITDA | - | - | - | - | -55.99M | -55.49M | -50.89M | -49.17M |
| Interest Expense | - | - | - | - | 1.07M | 3.23M | 3.51M | 3.15M |
| Pretax Income | - | - | - | - | -58.57M | -60.27M | -55.89M | -53.38M |
| Tax Provision | - | - | - | - | 353.00K | 571.00K | 500.00K | 626.00K |
| Net Income | -18.48M | -20.70M | -32.23M | -48.66M | -58.92M | -60.84M | -56.39M | -54.00M |
| Diluted EPS | - | - | -3.16 | -1.35 | -1.59 | -1.60 | -1.44 | -1.33 |
| R&D Expense | 6.99M | 6.05M | 7.46M | 13.06M | 15.40M | 18.08M | 17.57M | 19.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.53M | 263.71M | 235.17M | 193.68M | 177.78M | 162.85M | 129.29M |
| Total Equity | -149.39M | -167.33M | -187.38M | 226.13M | 193.24M | 154.01M | 118.31M | 85.81M | 54.12M |
| Cash & Equivalents | - | 4.12M | 14.77M | 231.56M | 148.48M | 101.74M | 83.55M | 70.91M | 69.75M |
| Long Term Debt | - | - | - | 17.37M | 17.41M | 17.23M | 35.09M | 34.00M | 36.99M |
| Total Liabilities | - | - | 35.57M | 37.57M | 41.93M | 39.67M | 59.47M | 77.04M | 75.17M |
| Current Liabilities | - | - | 14.16M | 12.53M | 17.55M | 18.49M | 23.16M | 24.44M | 20.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.39M | -20.77M | -30.63M | -41.39M | -45.08M | -37.61M | -31.54M | -32.38M |
| Investing Cash Flow | 200.00K | -14.23M | 12.69M | -46.26M | -4.22M | -2.01M | 17.48M | 30.48M |
| Financing Cash Flow | 12.11M | 45.62M | 234.83M | 4.46M | 2.42M | 21.40M | 1.36M | 833.00K |
| Capital Expenditure | -316.00K | -720.00K | -911.00K | -3.67M | -1.32M | -807.00K | -1.45M | -452.00K |
| Free Cash Flow | -18.71M | -21.48M | -31.54M | -45.06M | -46.40M | -38.42M | -32.98M | -32.83M |
| Share Buybacks | 0 | 12.00K | 21.00K | 26.00K | 27.00K | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 61.4% | 68.8% | 64.8% | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Operating Margin % | -75.2% | -54.7% | -98.8% | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Net Margin % | -92.4% | -63.5% | -98.5% | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| ROE % | 11.0% | 11.0% | -14.3% | -25.2% | -38.3% | -51.4% | -65.7% | -99.8% |
| ROCE % | - | -45.3% | -12.9% | -21.7% | -33.5% | -40.1% | -41.7% | -49.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Primecap Management Company | 10.74% | 4.61M | $10.98M |
| 2 | Morgan Stanley | 6.81% | 2.92M | $6.96M |
| 3 | Soleus Capital Management, L.P. | 6.49% | 2.79M | $6.64M |
| 4 | Vanguard Capital Management LLC | 3.80% | 1.63M | $3.88M |
| 5 | ExodusPoint Capital Management, LP | 2.85% | 1.22M | $2.91M |
| 6 | Almitas Capital LLC | 2.48% | 1.06M | $2.53M |
| 7 | Blackrock Inc. | 2.05% | 882.49K | $2.10M |
| 8 | Stonepine Capital Management, LLC | 1.90% | 815.44K | $1.94M |
| 9 | Jane Street Group, LLC | 1.77% | 758.23K | $1.80M |
| 10 | Braidwell LP | 1.75% | 752.54K | $1.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LUNG
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQZlJpZ1hVRWNzS2tLY0dsaUVPOUZFZlVOdk9lSFIxaUJZLUhXUnBMTU1CQTJQT0dkUHlPNlpxYUJXdzl5OTVLMk1Hbm1MemVZaU5rSFhxMEpValVleUxHa2poM254cGhwdzhHZldDTUlUUHpmTkkzc3VnOXJVSWFSaVA4VjFNV2hhM1dFa2…
Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQlM1T1ZBV0c4TU4weW1hSzdVbW1XY0lkd01DZmk0MDZna3ByRlI5ZnBRRzd5ODhLMFVNOWNpZ191ejhtanVSQXBDajI4cTktQkg1OGUzTVQ5Um83X3M0ejBlQ1pDWk8xTE1mQnNTc0ZSU3prZGJiNFE4R0RWa3hFWllKX0xscVpIZlNUUk…
Pulmonx (LUNG) CEO sells 41,882 shares to cover taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTmgtcEs0ZFhWaEtDOUp6MGlwekRlN2tJVF9aS3l2aEJ5N0dOTUs1eUdtczNaT0xxVjRzZWplTnpnb19HSFlmWU9fUUlCNll5OWNmMU9JV3FjN29XR1NwS29zRmhzT0dPemdPY0pET01lQ0RIVVBmSGJmTVY1RHM5SlgwanJKTnYwbFM5TH…
BIAF Stock Pops As Federal Lung Test Deal Fuels Momentum - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQdnZkWjRNaTFDOEhSTHR4NjFLNGNqRW1mZjMzUXpvaGcwZGNiaHpNRzRublVqZVRQVmJhaUxVYjlNa2JVR2N0YS01c2E1cFczcHlMNVkxMzdfSGE4eWF6NjIwQWVBQzlMR1dkRUR1d183TGNWeGpudjJnV0xNMV9hSm9ialE3Qng4Snc?oc…
Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNZzRwRlFaUTdONHd4ajBlNnF5WVVDajFfek1KeUVLUlhFWkpyQ25ZbHhMcElWMkt3eUREWkJLSFAwbWkyOVE3X09fM1V0U09WYWd4NThmcnZsUlp6OUVnajlvdjVDUFd3cUF2MUNfM1ZBYzZqTVkxdzcxMlZDY2FtY0VOVkhEX25KeVZhRU…
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYWVGSzc2MVJaNTdYYk9kZnF6U3pReFZYaTBObW9XcUM4dXZPWGZLTU5NMUpiZ0d5enVMdlQyN1gwdGNheExtdmF4cWM5UnYtcl9DWmRLMTloM2R4cExHMkZ2Njd2SWhYRHJ6OU9Xb0pfdDVsVklmQUVsR2U2NDZIdDhzQlJSb29wbXA2eX…
LUNG — Frequently Asked Questions
What is the current share price of Pulmonx Corporation (LUNG)?
As of 2026-09-07 16:24 PDT, Pulmonx Corporation (LUNG) trades at $2.21 on NasdaqGS. Its 52-week range is $1.17 to $2.60.
What is the market capitalisation of LUNG?
Pulmonx Corporation (LUNG) has a market capitalisation of $93.34M on NasdaqGS.
What is the P/E ratio of LUNG?
LUNG trades at a trailing price-to-earnings (P/E) ratio of -1.92. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.21.
What is the return on equity (ROE) of LUNG?
LUNG has a return on equity (ROE) of -88.87%. Its return on capital employed (ROCE) is -49.13%.
Is LUNG a good stock to buy?
This page provides a data-driven analysis of Pulmonx Corporation (LUNG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.